Amoéba
Develops natural microbiological solutions to manage bacterial and fungal risks.
ALMIB | PA
Overview
Corporate Details
- ISIN(s):
- FR0011051598 (+2 more)
- LEI:
- 9695005QNE7C8Z0LXU64
- Country:
- France
- Address:
- 38 AVENUE DES FRERES MONTGOLFIER, 69680 CHASSIEU
- Website:
- https://amoeba-nature.com/en/
- Sector:
- Manufacturing
- Industry:
- Manufacture of other chemical products
Description
Amoéba is a biotechnology company that develops natural microbiological solutions for managing bacterial and fungal risks. The company's core technology is based on the patented use of the amoeba *Willaertia magna* C2c Maky and its biocidal properties. Its primary focus is on agricultural biocontrol, offering a biofungicide derived from a mechanically lysed amoeba. This product targets plant diseases such as mildews, rusts, and powdery mildew, providing a biological alternative to chemical treatments. Amoéba has also developed applications for its technology in the treatment of bacterial risk in industrial water systems, on surfaces, and for chronic wounds.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Type / Size | Actions | |
|---|---|---|---|---|---|
| 2017-09-26 10:56 |
RAPPORT FINANCIER SEMESTRIEL au 30 juin 2017
|
French | PDF • 1000.2 KB | ||
| 2017-09-26 10:49 |
CP Rapport financier semestriel 2017
|
French | PDF • 470.2 KB | ||
| 2017-09-25 17:40 |
Rapport financier semestriel 2017
|
French | PDF • 470.2 KB | ||
| 2017-09-25 17:40 |
2017 Interim Financial Report
|
English | PDF • 466.0 KB | ||
| 2017-09-21 17:45 |
Des résultats semestriels 2017 conformes aux anticipations du Groupe
|
French | PDF • 401.8 KB | ||
| 2017-09-21 17:45 |
2017 half-year results in line with the Group’s expectations
|
English | PDF • 393.5 KB | ||
| 2017-09-14 17:40 |
AMOEBA signs a distribution agreement with DREWO
|
English | PDF • 398.1 KB | ||
| 2017-09-11 17:40 |
AMOEBA INFORME DE LA TENUE DU GROUPE DE TRAVAIL EUROPEEN SUR SON DOSSIER REGLEM…
|
French | PDF • 396.6 KB | ||
| 2017-09-11 17:40 |
AMOEBA COMMUNICATES ABOUT EUROPEAN WORKING GROUP HELD ON ITS REGULATORY DOSSIER
|
English | PDF • 386.4 KB | ||
| 2017-07-27 17:45 |
AMOEBA signe une Lettre d’Intention avec MOMAR Inc.
|
French | PDF • 410.8 KB | ||
| 2017-07-27 17:45 |
AMOEBA signs a Letter of Intent with MOMAR
|
English | PDF • 397.7 KB | ||
| 2017-07-04 17:45 |
Bilan semestriel du contrat de liquidité
|
French | PDF • 400.6 KB | ||
| 2017-07-04 17:45 |
Half-year review of the liquidity contract
|
English | PDF • 398.1 KB | ||
| 2017-06-27 17:40 |
AMOEBA et VISCUS BIOLOGICS annoncent un programme commun pour le traitement des…
|
French | PDF • 422.8 KB | ||
| 2017-06-27 17:40 |
AMOEBA and VISCUS BIOLOGICS announce a joint program for the treatment of multi…
|
English | PDF • 704.9 KB |
Automate Your Workflow. Get a real-time feed of all Amoéba filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Amoéba
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Amoéba via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2024-08-30 | N/A | Other | Buy | 6,300 | 3,609.90 EUR |
| 2024-08-29 | N/A | Other | Sell | 5,500 | 3,564.00 EUR |
| 2024-08-28 | N/A | Other | Buy | 3,200 | 1,782.08 EUR |
| 2024-08-27 | N/A | Other | Buy | 20,049 | 11,231.45 EUR |
| 2024-08-26 | N/A | Other | Buy | 31,107 | 17,441.69 EUR |
| 2024-08-22 | N/A | Other | Buy | 2,255 | 1,298.88 EUR |
| 2024-08-20 | N/A | Other | Buy | 16,664 | 8,838.59 EUR |
| 2024-08-19 | N/A | Other | Buy | 13,390 | 6,795.43 EUR |
| 2024-08-16 | N/A | Other | Buy | 6,745 | 3,468.28 EUR |
| 2024-08-09 | N/A | Other | Buy | 40,748 | 21,559.77 EUR |
Peer Companies
